Cognition Therapeutics Wins Patent for CT1812 Crystalline Form
The patent expires in 2045 and could be extended by up to five years upon FDA approval. The company plans to begin manufacturing the form in Q1 2027 for a registrational DLB trial.
The patent expires in 2045 and could be extended by up to five years upon FDA approval. The company plans to begin manufacturing the form in Q1 2027 for a registrational DLB trial.